GE, Novation sign for injectable contrast media
GE Healthcare and Novation, the supply company of VHA Inc. and the University HealthSystem Consortium (UHC), inked a single-source contract to provide VHA and UHC healthcare organizations access to GE's injectable x-ray, MRI, and ultrasound contrast media products, many of which are supplied under Novation's private label brand, Novaplus.
The contract takes effect April 1 and runs through March 31, 2008.
Under the terms of the agreement, GE will provide VHA and UHC members access to a broad range of contrast media including Omnipaque (iohexol) Injection and Omniscan (gadodiamide) Injection. Also included in the agreement are: Visipaque (iodixanol), a nonionic isosmolar contrast agent, Optison (Perflutren protein-Type A microspheres for Injection, USP), a contrast agent for cardiovascular ultrasound imaging, and Hypaque (diatrizoate).
The contract takes effect April 1 and runs through March 31, 2008.
Under the terms of the agreement, GE will provide VHA and UHC members access to a broad range of contrast media including Omnipaque (iohexol) Injection and Omniscan (gadodiamide) Injection. Also included in the agreement are: Visipaque (iodixanol), a nonionic isosmolar contrast agent, Optison (Perflutren protein-Type A microspheres for Injection, USP), a contrast agent for cardiovascular ultrasound imaging, and Hypaque (diatrizoate).